Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.

Cline active as junior mulls strategic options: Canadian market movers

Elizabeth Walters Elizabeth Walters, Stockhouse
0 Comments| January 23, 2013

On Tuesday, the top TSX mover was Research In Motion Ltd. (TSX: T.RIM, Stock Forum). The stock lost 1.92% and was trading at $17.4 on volume of 6.3 million. The wireless innovator said that its new Enterprise Mobility Management solution, BlackBerry Enterprise Service 10, is now available for download.

The BlackBerry Enterprise Service 10 offers mobile device management, mobile application management and secure mobile connectivity, and delivers a cost-efficient and reliable solution for business customers.

Cline Mining Corp. (TSX: T.CMK, Stock Forum) was the second most active stock on the TSX. It soared 45.45% and was trading at $0.080 on volume of 6 million shares. On Jan. 22, the coal coal-focused company said it retained GMP Securities L.P. as its exclusive financial advisor. 

With the assistance of GMP, the company is in the process of soliciting proposals for possible alternative transactions with a view to maximizing value for the company and its stakeholders.

Pacific Coal Resources Ltd. (TSX: V.PAK, Stock Forum) was the volume leader on the TSX Venture Exchange. It rose 1.89% and was trading at $0.27 on volume of 3.8 million. The coal mining company had no related news to explain the high volume of trading.

The second most active stock on the TSX Venture was Med BioGene Inc. (TSX: V.MBI, Stock Forum). It gained 50% and was trading at $0.045 after 3.8 million shares changed hands. The science-based company announced that Precision Therapeutics has successfully completed their previously announced clinical studies to validate the use of LungExpress Dx with tissue preserved by RNAlater, a molecular fixative.

On April 15, 2011, Precision and Med BioGene closed their commercialization, license and research reimbursement agreement. The agreement provides to Precision exclusive global rights to develop and commercialize LungExpress Dx.


Rate this article
3 stars




No comments yet. Be first to comment!

Leave a Message

You must be logged in to access this feature.